Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

RMD Open. 2017 Sep 12;3(2):e000492. doi: 10.1136/rmdopen-2017-000492. eCollection 2017.

Eric Toussirot^{1

2

3

4}, Hubert Marotte^{5

6}

¹ INSERM CIC-1431, Clinical Investigation Center in Biotherapy, University Hospital of Besançon, Besançon, France.
² Fédération Hospitalo-Universitaire INCREASE, University Hospital of Besançon, Besançon, France.
³ Department of Rheumatology, University Hospital of Besançon, Besançon, France.
⁴ Department of Therapeutics and EPILAB EA4266, University of Bourgogne Franche-Comté, Epigénétique des Infections Virales et des Maladies Inflammatoires, Besançon, France.
⁵ SAINBIOSE INSERM U1059, University of Lyon, Saint-Etienne, France.
⁶ Department of Rheumatology, Hôpital Nord, University Hospital, Saint-Etienne, France.

No abstract available

Keywords: innovator biological agent – biosimilar – immunogenicity.

Publication types